Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% of its employees and cutting back internal R&D work to focus on lead program emiltatug ledadotin (Emi-Le).
https://www.fiercebiotech.com/biotech/mersana-makes-emi-le-one-laying-55-staff-narrows-focus-b7-h4-adc